Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% SEOUL, South Korea, Sept. 13, 2026...
Covered in this story
What has happened since
- MetLife is up 1.1% since this was published, 40 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on MetLife
- Evercore ISI: $96.2 → $106 by Aug 2027 · In Line via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MET yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on MetLife →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.